Aquayamycin: Difference between revisions
CSV import |
No edit summary |
||
| Line 30: | Line 30: | ||
{{stub}} | {{stub}} | ||
== Aquayamycin == | == Aquayamycin == | ||
<gallery> | <gallery> | ||
File:Aquayamycin.svg|Aquayamycin | File:Aquayamycin.svg|Aquayamycin | ||
</gallery> | </gallery> | ||
Latest revision as of 19:02, 16 March 2025
Aquayamycin is a benzenoid antibiotic that is derived from the Streptomyces genus of Actinobacteria. It is a member of the angucycline group of antibiotics, which are known for their broad spectrum of activity against various bacteria and fungi. Aquayamycin has been found to exhibit potent antitumor activity, making it a potential candidate for cancer therapy.
History[edit]
Aquayamycin was first isolated in 1973 from a strain of Streptomyces found in a soil sample from Japan. The compound was named after the location where the soil sample was collected, the town of Aqua in Yamaguchi Prefecture.
Structure and Biosynthesis[edit]
Aquayamycin is a tetracyclic compound with a unique [[benz[a]anthracene]] skeleton. Its biosynthesis involves the condensation of eight malonyl-CoA units by a polyketide synthase (PKS) complex, followed by a series of modifications including cyclization, oxidation, and glycosylation.
Biological Activity[edit]
Aquayamycin has been shown to have potent antitumor activity against a variety of cancer cell lines, including breast cancer, lung cancer, and colon cancer. It is thought to exert its antitumor effects by inhibiting DNA synthesis and inducing apoptosis in cancer cells.
Clinical Use[edit]
While aquayamycin has shown promise in preclinical studies, it has not yet been approved for use in humans. Further research is needed to determine its safety and efficacy in clinical trials.
